Last reviewed:December 2019
Last updated:February  2019



History and exam

Key diagnostic factors

  • presence of risk factors
  • Family history
  • onset in childhood (MPS, Pompe's, Gaucher's, Fabry's, Niemann-Pick type A)
  • onset in adolescence (Fabry's, Pompe's, Gaucher's types 1, 3, MPS, Niemann-Pick types B, C)
  • onset in adulthood (Fabry's, Gaucher's type 1, Pompe's)
  • hepatomegaly and/or splenomegaly
  • hyperacusis
  • history of renal failure
  • skin rash/cutaneous lesions
  • large head circumference
  • macular 'cherry red spot' on ophthalmoscopy
  • optic atrophy or retinitis pigmentosa on ophthalmoscopy
  • corneal clouding on ophthalmoscopy
  • fatigue

Other diagnostic factors

  • neurodevelopmental delay
  • hearing impairment/sudden deafness
  • cataract on ophthalmoscopy
  • eye movement disorder
  • progressive dementia and ataxia or gait disturbance
  • failure to thrive
  • joint contracture
  • depression
  • skeletal abnormalities including spinal gibbus
  • hydrocephalus
  • history of recurrent respiratory tract infections
  • psychosis
  • movement disorders
  • premature stroke/transient ischaemic attack
  • cardiomegaly
  • valvular cardiac disease

Risk factors

  • male sex (mucopolysaccharidosis [MPS] II, Fabry's disease)
  • Ashkenazi ethnicity

Diagnostic investigations

Treatment algorithm


Consultant Haematologist

Royal Free Hospital

Professor in Haematology

University College London




ABM has received research funding, travel grants for educational meetings, and consultancy fees from Sanofi Genzyme, Shire HGT, Actelion, Biomarin, Protalix, and Amicus. He is also an author of a number of references cited in this topic.

Peer reviewersVIEW ALL

Associate Professor

Departments of Neurology and Pediatrics

NYU School of Medicine

New York



GMP declares that he has no competing interests.

Consultant Paediatrician

Paediatric Metabolic Unit

Cambridge University Hospitals




UR has received travel grants, honoraria for lectures, and funding for clinical trials from Shire HGT, Genzyme, and Actelion.

Head of Department

Children's Hospital

University of Mainz




MB has been reimbursed by Shire, the manufacturer of Elaprase and Replagal, for attending several conferences, for running educational programs and for consulting. MB has received honoraria for speaking from Genzyme (the manufacturer of Myozyme, Fabrazyme, Aldurazyme, and Cerezyme) and Actelion (the manufacturer of Zavesca). MB is an author of a number of references cited in this topic.

Associate Professor of Public Health

Director of Research

Gippsland Medical School

Monash University




EVV declares that he has no competing interests.

Use of this content is subject to our disclaimer